Related Experiment Video
Updated: Apr 7, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted
J B Sarma1, B Marshall1, V Cleeve1
1Department of Microbiology, Northumbria Healthcare NHS Foundation Trust, UK.
Background:
Antimicrobial stewardship is a key component in the reduction of healthcare-associated infections, particularly Clostridium difficile infection (CDI). We successfully restricted the use of cephalosporins and, subsequently, fluoroquinolones. From an endemically high level of >280 cases per year in 2007-08, the number of CDIs reduced to 72 cases in 2011-12.
Aim:
To describe the implementation and impact of fluoroquinolone restriction on CDI.
Methods:
This was an interrupted time-series analysis pre and post fluoroquinolone restriction for 60 months based on a Poisson distribution model.
Findings:
In June 2008, fluoroquinolone consumption halved to about 5 defined daily doses (DDD) per 100 occupied bed-days (OBD). This was followed by a significant fall in CDI number [rate ratio (RR): 0.332; 95% confidence interval (CI): 0.240-0.460] which remained low over the subsequent months. Subsequently, fluoroquinolone consumption was further reduced to about 2 DDD/100 OBD in June 2010 accompanied by further reduction in CDI rate (RR: 0.394; 95% CI: 0.199-0.781). In a univariate Poisson model the CDI rate was associated with fluoroquinolone usage (RR: 1.086; 95% CI: 1.077-1.094).
Conclusion:
We conclude that in an environment where cephalosporin usage is already low, the reduction in fluoroquinolone usage was associated with an immediate, large, and significant reduction in CDI cases.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Gene Regulation in Microbial Communities: Quorum Sensing
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

